- Home
- GH
as 11-21-2024 12:35pm EST
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 2.7B | IPO Year: | 2018 |
| Target Price: | $39.07 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.81 - $37.04 | Next Earning Date: | 11-06-2024 |
| Revenue: | $692,256,000 | Revenue Growth: | 29.20% |
| Revenue Growth (this year): | 31% | Revenue Growth (next year): | 17.55% |
Stock Insider Trading Activity of Guardant Health Inc. (GH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kalia Kumud | GH | Chief Information Officer | Nov 18 '24 | Sell | $29.25 | 7,000 | $204,722.00 | 17,744 | |
| CLARK IAN T | GH | Director | Nov 12 '24 | Sell | $29.48 | 8,318 | $244,929.50 | 15,677 |
Latest Guardant Health Inc. News
GH Breaking Stock News: Dive into GH Ticker-Specific Updates for Smart Investing
Investor's Business Daily
a day ago
Guardant Health Stock Sees RS Rating Jump To 83
Business Wire
8 days ago
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Motley Fool
9 days ago
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Simply Wall St.
13 days ago
Guardant Health Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Motley Fool
14 days ago
Why Guardant Health Stock Blasted 13% Higher on Thursday
Investor's Business Daily
14 days ago
Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop
Morningstar Research
14 days ago
Analyst Report: Guardant Health, Inc.
GuruFocus.com
14 days ago
Guardant Health Inc (GH) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
Compare GH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GH Guardant Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.